Cerus to Release Second Quarter 2013 Results on July 30, 2013

  Cerus to Release Second Quarter 2013 Results on July 30, 2013

Business Wire

CONCORD, Calif. -- July 9, 2013

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter
results will be released on Tuesday, July 30, 2013, after the close of the
stock market. The company will host a conference call and webcast at 4:15 PM
ET that afternoon, during which management will discuss the Company’s
financial results and provide a general business overview and outlook.

To access the live webcast, please visit the Investor Relations page of the
Cerus website at http://www.cerus.com/ir. Alternatively, you may access the
live conference call by dialing 866-235-9006 (U.S.) or 631-291-4549
(international).

A replay will be available on the company’s website, or by dialing
855-859-2056 (U.S.) or 404-537-3406 (international) and entering conference ID
number 31978377. The replay will be available approximately three hours after
the call through August 12, 2013.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of
blood safety. The company’s INTERCEPT Blood System has been demonstrated to
inactivate a broad range of viruses, bacteria and parasites that may be
present in donated blood, including established threats such as hepatitis B
and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such
as influenza, malaria and dengue. Cerus currently markets and sells the
INTERCEPT Blood System for both platelets and plasma in Europe, the
Commonwealth of Independent States, the Middle East and selected countries in
other regions around the world. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma and platelets.
The INTERCEPT red blood cell system is in clinical development. See
http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Contact:

Cerus Corporation
Kevin D. Green, 925-288-6138
Vice President, Finance & CFO